Align Technology, Inc. vs Manhattan Associates Inc — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while Manhattan Associates Inc trades at $192.8 (market cap $11.38B). The key difference: Align Technology, Inc. and Manhattan Associates Inc are close in size by market cap. Which is the better fit depends on your goals.
| ALGN | MANH | |
|---|---|---|
Market Cap | $12.29B | $11.38B |
Sector | Health | Technology |
52-Week High | $197.51 | $220.19 |
52-Week Low | $124.88 | $120.88 |
Enterprise Value | $11.30B | $11.25B |
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.
The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.
MANH is trading at $192.63, down 1.56% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q2 2026 earnings, beating EPS estimates with $1.39 versus $1.32 expected, driven by 26% cloud revenue growth. However, valuation ratios remain elevated with a P/E of 55.93 and P/B of 72.26, indicating high investor expectations. Recent news highlights an ongoing legal investigation into fiduciary duties by the Rosen Law Firm, creating a mixed sentiment backdrop.
The outlook for MANH is cautiously optimistic, with a consensus price target of $210.33 offering 9.2% upside potential. Key opportunities include sustained cloud growth and strong profitability metrics like a 96.38% ROE. Risks involve the high valuation, potential legal overhangs from the investigation, and any slowdown in enterprise software demand. Institutional analysts maintain an 80% buy rating, suggesting confidence in execution despite near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →